Literature DB >> 18069766

Predictive factors for interferon and ribavirin combination therapy in patients with chronic hepatitis C.

Joonho Yoon1, Jong In Lee, Soon Koo Baik, Kwang Ho Lee, Joon Hyung Sohn, Hyean Woo Lee, Jun Namkung, Sei Jin Chang, Jong Whan Choi, Hyun Won Kim, Byung-Il Yeh.   

Abstract

AIM: To confirm the predictive factors for interferon (IFN)-alpha and ribavirin combination therapy for chronic hepatitis patients with hepatitis C virus (HCV) genotype 1b.
METHODS: HCV RNA from 50 patients infected with HCV genotype 1b was studied by cloning and sequencing of interferon sensitivity determining region (ISDR), PKR-eIF2alpha phosphorylation homology domain (PePHD). Patients were treated with IFN-alpha and ribavirin for 6 mo and grouped by effectiveness of the therapy. A variety of factors were analyzed.
RESULTS: Our data showed that age, HCV RNA titer, and ISDR type could be used as the predictive factors for combined IFN-alpha and ribavirin efficacy. Characteristically, mutations in PePHD appeared only when the combination therapy was effective. Other factors, such as sex and alanine aminotransferase (ALT) level, were not related to its efficacy. Adjusting for age and HCV RNA titer indicated that the ISDR type was the most potent predictive factor.
CONCLUSION: HCV RNA ISDR type is an important factor for predicting efficacy of IFN-alpha and ribavirin combination therapy in Korean patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18069766      PMCID: PMC4171236          DOI: 10.3748/wjg.v13.i46.6236

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  53 in total

1.  Interferon-alpha for chronic hepatitis C: an analysis of pretreatment clinical predictors of response.

Authors:  L Pagliaro; A Craxí; C Cammaá; F Tiné; V Di Marco; O Lo Iacono; P Almasio
Journal:  Hepatology       Date:  1994-04       Impact factor: 17.425

2.  Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa.

Authors:  G Squadrito; F Leone; M Sartori; B Nalpas; P Berthelot; G Raimondo; S Pol; C Bréchot
Journal:  Gastroenterology       Date:  1997-08       Impact factor: 22.682

3.  Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C.

Authors:  M Martinot-Peignoux; P Marcellin; M Pouteau; C Castelnau; N Boyer; M Poliquin; C Degott; I Descombes; V Le Breton; V Milotova
Journal:  Hepatology       Date:  1995-10       Impact factor: 17.425

4.  Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection.

Authors:  N Enomoto; I Sakuma; Y Asahina; M Kurosaki; T Murakami; C Yamamoto; Y Ogura; N Izumi; F Marumo; C Sato
Journal:  N Engl J Med       Date:  1996-01-11       Impact factor: 91.245

5.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

Authors:  J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

6.  Why is the interferon sensitivity-determining region (ISDR) system useful in Japan?

Authors:  I Nakano; Y Fukuda; Y Katano; S Nakano; T Kumada; T Hayakawa
Journal:  J Hepatol       Date:  1999-06       Impact factor: 25.083

7.  Long-term response to interferon alpha is unrelated to "interferon sensitivity determining region" variability in patients with chronic hepatitis C virus-1b infection.

Authors:  G Squadrito; M E Orlando; I Cacciola; M G Rumi; M Artini; A Picciotto; O Loiacono; R Siciliano; M Levrero; G Raimondo
Journal:  J Hepatol       Date:  1999-06       Impact factor: 25.083

8.  Mutations in the NS5A region do not predict interferon-responsiveness in american patients infected with genotype 1b hepatitis C virus.

Authors:  R T Chung; A Monto; J L Dienstag; L M Kaplan
Journal:  J Med Virol       Date:  1999-08       Impact factor: 2.327

9.  Influence of the genetic heterogeneity of the ISDR and PePHD regions of hepatitis C virus on the response to interferon therapy in chronic hepatitis C.

Authors:  F Puig-Basagoiti; J C Sáiz; X Forns; S Ampurdanès; M Giménez-Barcons; S Franco; A Sánchez-Fueyo; J Costa; J M Sánchez-Tapias; J Rodés
Journal:  J Med Virol       Date:  2001-09       Impact factor: 2.327

10.  Variation in the hepatitis C virus NS5a region in relation to hypervariable region 1 heterogeneity during interferon treatment.

Authors:  J Odeberg; Z Yun; A Sönnerborg; O Weiland; J Lundeberg
Journal:  J Med Virol       Date:  1998-09       Impact factor: 2.327

View more
  1 in total

Review 1.  Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C.

Authors:  Shinya Maekawa; Nobuyuki Enomoto
Journal:  J Gastroenterol       Date:  2009       Impact factor: 7.527

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.